BACKGROUND AND PURPOSE: The aim of this study was to explore the effects of CB(2) receptor agonist and antagonist in the regulation of anxiety-like behaviours. EXPERIMENTAL APPROACHES: Effects of acute and chronic treatment with the CB(2) receptor agonist JWH133 and CB(2) receptor antagonist AM630 were evaluated in the light-dark box (LDB) and elevated plus maze (EPM) tests in Swiss ICR mice. CB(2) receptor, GABA(A) α(2) and GABA(A) γ(2) gene and protein expression in the cortex and amygdala of mice chronically treated with JWH133 or AM630 were examined by RT-PCR and Western blot. Effects of chronic AM630 treatment were evaluated in spontaneously anxious DBA/2 mice in LDB. KEY RESULTS: Acute JWH133 treatment failed to produce any effect. Acute AM630 treatment increased anxiety and was blocked by pre-treatment with JWH133. Chronic JWH133 treatment increased anxiety-like behaviour whereas chronic AM630 treatment was anxiolytic in LDB and EPM tests. Chronic AM630 treatment increased gene and reduced protein expression of CB(2) receptors, GABA(A) α(2) and GABA(A) γ(2) in cortex and amygdala. Chronic JWH133 treatment resulted in opposite gene and protein alterations. In addition, chronic AM630 administration decreased the anxiety of DBA/2 mice in the LDB test. CONCLUSIONS AND IMPLICATIONS: The opposing behavioural and molecular changes observed after chronic treatment with AM630 or JWH133 support the key role of CB(2) receptors in the regulation of anxiety. Indeed, the efficacy of AM630 in reducing the anxiety of the spontaneously anxious DBA/2 strain of mice strengthens the potential of the CB(2) receptor as a new target in the treatment of anxiety-related disorders.
BACKGROUND AND PURPOSE: The aim of this study was to explore the effects of CB(2) receptor agonist and antagonist in the regulation of anxiety-like behaviours. EXPERIMENTAL APPROACHES: Effects of acute and chronic treatment with the CB(2) receptor agonist JWH133 and CB(2) receptor antagonist AM630 were evaluated in the light-dark box (LDB) and elevated plus maze (EPM) tests in Swiss ICR mice. CB(2) receptor, GABA(A) α(2) and GABA(A) γ(2) gene and protein expression in the cortex and amygdala of mice chronically treated with JWH133 or AM630 were examined by RT-PCR and Western blot. Effects of chronic AM630 treatment were evaluated in spontaneously anxious DBA/2 mice in LDB. KEY RESULTS: Acute JWH133 treatment failed to produce any effect. Acute AM630 treatment increased anxiety and was blocked by pre-treatment with JWH133. Chronic JWH133 treatment increased anxiety-like behaviour whereas chronic AM630 treatment was anxiolytic in LDB and EPM tests. Chronic AM630 treatment increased gene and reduced protein expression of CB(2) receptors, GABA(A) α(2) and GABA(A) γ(2) in cortex and amygdala. Chronic JWH133 treatment resulted in opposite gene and protein alterations. In addition, chronic AM630 administration decreased the anxiety of DBA/2 mice in the LDB test. CONCLUSIONS AND IMPLICATIONS: The opposing behavioural and molecular changes observed after chronic treatment with AM630 or JWH133 support the key role of CB(2) receptors in the regulation of anxiety. Indeed, the efficacy of AM630 in reducing the anxiety of the spontaneously anxious DBA/2 strain of mice strengthens the potential of the CB(2) receptor as a new target in the treatment of anxiety-related disorders.
Authors: Marja D Van Sickle; Marnie Duncan; Philip J Kingsley; Abdeslam Mouihate; Paolo Urbani; Ken Mackie; Nephi Stella; Alexandros Makriyannis; Daniele Piomelli; Joseph S Davison; Lawrence J Marnett; Vincenzo Di Marzo; Quentin J Pittman; Kamala D Patel; Keith A Sharkey Journal: Science Date: 2005-10-14 Impact factor: 47.728
Authors: Kenneth J Valenzano; Laykea Tafesse; Gary Lee; James E Harrison; Jamie M Boulet; Susan L Gottshall; Lilly Mark; Michelle S Pearson; Wendy Miller; Shen Shan; Leyana Rabadi; Yakov Rotshteyn; Suzanne M Chaffer; Paul I Turchin; David A Elsemore; Mathew Toth; Lee Koetzner; Garth T Whiteside Journal: Neuropharmacology Date: 2005-04 Impact factor: 5.250
Authors: G Griffin; E J Wray; Q Tao; S D McAllister; W K Rorrer; M M Aung; B R Martin; M E Abood Journal: Eur J Pharmacol Date: 1999-07-14 Impact factor: 4.432
Authors: Emmanuel S Onaivi; Hiroki Ishiguro; Jian-Ping Gong; Sejal Patel; Alex Perchuk; Paul A Meozzi; Lester Myers; Zoila Mora; Patricia Tagliaferro; Eileen Gardner; Alicia Brusco; Babatunde E Akinshola; Qing-Rong Liu; Bruce Hope; Shinya Iwasaki; Tadao Arinami; Lindsey Teasenfitz; George R Uhl Journal: Ann N Y Acad Sci Date: 2006-08 Impact factor: 5.691
Authors: M Beltramo; N Bernardini; R Bertorelli; M Campanella; E Nicolussi; S Fredduzzi; A Reggiani Journal: Eur J Neurosci Date: 2006-03 Impact factor: 3.386
Authors: Emmanuel S Onaivi; Hiroki Ishiguro; Jian-Ping Gong; Sejal Patel; Paul A Meozzi; Lester Myers; Alex Perchuk; Zoila Mora; Patricia A Tagliaferro; Eileen Gardner; Alicia Brusco; B Emmanuel Akinshola; Bruce Hope; Javier Lujilde; Toshiya Inada; Shinya Iwasaki; David Macharia; Lindsey Teasenfitz; Tadao Arinami; George R Uhl Journal: PLoS One Date: 2008-02-20 Impact factor: 3.240
Authors: Hai-Ying Zhang; Ming Gao; Qing-Rong Liu; Guo-Hua Bi; Xia Li; Hong-Ju Yang; Eliot L Gardner; Jie Wu; Zheng-Xiong Xi Journal: Proc Natl Acad Sci U S A Date: 2014-11-03 Impact factor: 11.205
Authors: Torbjörn U C Järbe; Sherrica Tai; Brian J LeMay; Spyros P Nikas; Vidyanand G Shukla; Alexander Zvonok; Alexandros Makriyannis Journal: Psychopharmacology (Berl) Date: 2011-10-12 Impact factor: 4.530